This is of interest, as there are elevated levels of phosphorylated NF-κB after CD40 stimulation in MS-derived B cells (50), and the CD40 risk variant is related to the lower expression of CD40, affecting impaired B cell functions (1, 51, 52). This evidence concerns the gene NFKB1 and myeloid sarcoma.